1420 studies found for:    Open Studies | "Lymphoma"
Show Display Options
RSS Create an RSS feed from your search for:
Open Studies | "Lymphoma"
Need help? See RSS Feeds
Choose a feed type:
Show studies first received on any dateShow studies that were first received in the last 14 days
Show studies last updated date on any dateShow studies that were added or modified in the last 14 days
Rank Status Study
1 Not yet recruiting A Phase II Study of Single Agent Brentuximab Vedotin in Relapsed/Refractory CD30 Low (<10%) Mature T Cell Lymphoma (TCL)
Conditions: T-cell Lymphoma;   Angioimmunoblastic T-cell Lymphoma;   Hepato-splenic T-cell Lymphoma;   Adult T-cell Leukemia/Lymphoma;   Enteropathy Associated T-cell Lymphoma;   NK T-cell Lymphoma;   Transformed Mycosis Fungoides
Intervention: Drug: Brentuximab vedotin
2 Recruiting A Trial Comparing the Two High-dose Chemotherapies BeEAM and BEAM Given Before Autologous Stem Cell Transplantation (ASCT) in Lymphoma Patients (BEB-trial)
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular;   Lymphoma, Mantle-Cell
Interventions: Drug: BeEAM;   Drug: BEAM
3 Recruiting Dose-Adjusted EPOCH Chemotherapy and Rituximab (CD20+) in Previously Untreated Aggressive Non-Hodgkin's Lymphoma
Conditions: Diffuse Large B-Cell Lymphoma (DLBCL);   Primary Meidastinal Lymphoma;   Burkitt Lymphoma;   Anaplastic Large-Cell Lymphoma;   Gray Zone Lymphoma
Interventions: Drug: EPOCH;   Biological: Rituximab
4 Recruiting Treatment Study of Denintuzumab Mafodotin (SGN-CD19A) Plus RICE Versus RICE Alone for Diffuse Large B-Cell Lymphoma
Conditions: Lymphoma, B-cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular, Grade 3b;   Follicular Lymphoma, Grade 3b
Interventions: Drug: denintuzumab mafodotin;   Drug: rituximab;   Drug: ifosfamide;   Drug: carboplatin;   Drug: etoposide
5 Unknown  Trial for the Treatment of Newly Diagnosed Mature B-Cell Acute Lymphoblastic Leukemia (B-ALL), Burkitt's Non-Hodgkin's Lymphoma (NHL) and Other High-Grade Lymphoma in Adults
Conditions: Burkitt's Lymphoma;   Burkitt's Leukemia;   Mediastinal Neoplasms;   Lymphoblastic Lymphoma;   Large Cell Anaplastic Lymphoma
Interventions: Drug: Adriamycin;   Drug: Cyclophosphamide;   Drug: Cytarabine;   Drug: Dexamethasone/Prednisolone;   Drug: VP16;   Drug: Ifosfamide;   Drug: Methotrexate;   Drug: G-CSF;   Drug: Rituximab;   Drug: Vincristine/Vindesine;   Procedure: Irradiation (in specific conditions)
6 Recruiting A Study of Duvelisib in Combination With Rituximab and Bendamustine vs Placebo in Combination With Rituximab and Bendamustine in Subjects With Previously-Treated Indolent Non-Hodgkin Lymphoma (BRAVURA)
Conditions: Indolent Non-Hodgkin's Lymphoma;   Follicular Lymphoma;   Small Lymphocytic Lymphoma;   Marginal Zone Lymphoma
Interventions: Drug: Duvelisib;   Drug: Placebo;   Drug: Rituximab;   Drug: Bendamustine
7 Recruiting A Phase 1 Multiple Ascending Dose Study of DS-3201b in Japanese Subjects With Lymphomas
Conditions: Lymphoma;   Lymphoma, B-cell;   Lymphoma, Follicular;   Adult T-Cell Leukemia Lymphoma (ATLL)
Intervention: Drug: DS-3201b
8 Recruiting An Efficacy and Safety Proof of Concept Study of Daratumumab in Relapsed/Refractory Mantle Cell Lymphoma, Diffuse Large B-Cell Lymphoma, and Follicular Lymphoma
Conditions: Lymphoma, Mantle-Cell;   Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
Intervention: Drug: Daratumumab
9 Recruiting Phase II Study of Dose-Adjusted EPOCH-Rituximab in Adults With Untreated Burkitt Lymphoma and c-MYC+ Diffuse Large B-Cell Lymphoma
Conditions: Burkitt Lymphoma;   Diffuse Large B-cell Lymphoma, c-MYC Positive;   Plasmablastic Lymphoma
Interventions: Drug: EPOCH-R;   Drug: EPOCH-RR
10 Recruiting Study of BKM120 & Rituximab in Patients With Relapsed or Refractory Indolent B-Cell Lymphoma
Conditions: Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: PI3K inhibitor BKM120;   Biological: rituximab;   Other: Pharmacodynamics;   Other: Correlative studies
11 Recruiting CPI-613, Bendamustine Hydrochloride, and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   B-cell Chronic Lymphocytic Leukemia;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Drug: 6,8-bis(benzylthio)octanoic acid;   Drug: bendamustine hydrochloride;   Biological: rituximab;   Other: laboratory biomarker analysis
12 Recruiting Treatment for Advanced B-Cell Lymphoma
Conditions: Diffuse Large Cell Lymphoma;   Burkitt's Lymphoma;   High Grade B-cell Lymphoma
Interventions: Drug: Rituximab;   Drug: IT Cytarabine
13 Recruiting CHOP vs GEM-P in 1st Line Treatment of T-cell Lymphoma, Multicentre Phase II Study
Conditions: Peripheral T-cell Lymphoma NOS;   Anaplastic Large Cell Lymphoma, ALK-Negative;   Angioimmunoblastic T-cell Lymphoma;   Hepatosplenic Gamma/ Delta T-cell Lymphoma
Interventions: Drug: Cyclophosphamide;   Drug: Gemcitabine;   Drug: Doxorubicin;   Drug: Vincristine;   Drug: Prednisolone;   Drug: methylprednisolone;   Drug: Cisplatin
14 Recruiting Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction
Conditions: Adult Mixed Glioma;   Adult Pineal Gland Astrocytoma;   Adult Solid Neoplasm;   AIDS Related Immunoblastic Lymphoma;   AIDS-Related Burkitt Lymphoma;   AIDS-Related Diffuse Large Cell Lymphoma;   AIDS-Related Diffuse Mixed Cell Lymphoma;   AIDS-Related Diffuse Small Cleaved Cell Lymphoma;   AIDS-Related Hodgkin Lymphoma;   AIDS-Related Lymphoblastic Lymphoma;   AIDS-Related Lymphoma;   AIDS-Related Primary Central Nervous System Lymphoma;   Glioma;   Lymphoma;   Recurrent Adult Brain Neoplasm;   Recurrent Adult Soft Tissue Sarcoma;   Recurrent Bladder Carcinoma;   Recurrent Breast Carcinoma;   Recurrent Chronic Lymphocytic Leukemia;   Recurrent Colorectal Carcinoma;   Recurrent Cutaneous T-Cell Non-Hodgkin Lymphoma;   Recurrent Head and Neck Carcinoma;   Recurrent Lung Carcinoma;   Recurrent Mature T- and NK-Cell Non-Hodgkin Lymphoma;   Recurrent Melanoma;   Recurrent Pancreatic Carcinoma;   Recurrent Prostate Carcinoma;   Recurrent Renal Cell Carcinoma;   Recurrent Thyroid Gland Carcinoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Cutaneous T-Cell Non-Hodgkin Lymphoma;   Refractory Mature T-Cell and NK-Cell Non-Hodgkin Lymphoma
Interventions: Other: Pharmacological Study;   Drug: Romidepsin
15 Recruiting Phase I Dose-finding and Preliminary Efficacy Study of the Istodax® in Combination With Doxil® for the Treatment of Adults With Relapsed or Refractory Cutaneous T-cell Lymphoma
Conditions: Lymphoma;   T-Cell Lymphoma;   Cutaneous Lymphoma
Interventions: Drug: Istodax;   Drug: Doxil
16 Unknown  Helicobacter – Lymphoma – Radiation Part I: Eradication, Part II: Radiation
Conditions: Lymphoma;   Lymphoma, Non-Hodgkin
Interventions: Drug: proton pump inhibitor;   Drug: clarithromycin;   Drug: amoxicillin;   Drug: metronidazole;   Procedure: radiation therapy
17 Not yet recruiting Rituximab, Romidepsin, and Lenalidomide in Treating Patients With Recurrent or Refractory B-cell Non-Hodgkin Lymphoma
Conditions: B-cell Adult Acute Lymphoblastic Leukemia;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Nodal Marginal Zone B-cell Lymphoma;   Recurrent Adult Acute Lymphoblastic Leukemia;   Recurrent Adult Burkitt Lymphoma;   Recurrent Adult Diffuse Large Cell Lymphoma;   Recurrent Adult Diffuse Mixed Cell Lymphoma;   Recurrent Adult Diffuse Small Cleaved Cell Lymphoma;   Recurrent Adult Grade III Lymphomatoid Granulomatosis;   Recurrent Adult Immunoblastic Large Cell Lymphoma;   Recurrent Adult Lymphoblastic Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Small Lymphocytic Lymphoma;   Refractory Hairy Cell Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   Testicular Lymphoma;   Waldenström Macroglobulinemia
Interventions: Biological: rituximab;   Drug: lenalidomide;   Drug: romidepsin;   Other: laboratory biomarker analysis
18 Recruiting Salvia Hispanica Seed in Reducing Risk of Disease Recurrence in Patients With Non-Hodgkin Lymphoma
Conditions: Adult Nasal Type Extranodal NK/T-Cell Lymphoma;   Adult T-Cell Leukemia/Lymphoma;   Anaplastic Large Cell Lymphoma;   Angioimmunoblastic T-Cell Lymphoma;   B Lymphoblastic Leukemia/Lymphoma;   Blastic Plasmacytoid Dendritic Cell Neoplasm;   Burkitt Leukemia;   Central Nervous System Lymphoma;   Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma;   Diffuse Large B-Cell Lymphoma;   Enteropathy-Associated T-Cell Lymphoma;   Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue;   Grade 1 Follicular Lymphoma;   Grade 2 Follicular Lymphoma;   Grade 3 Follicular Lymphoma;   Hepatosplenic T-Cell Lymphoma;   Hodgkin Lymphoma;   Lymphoplasmacytic Lymphoma;   Mantle Cell Lymphoma;   Mediastinal (Thymic) Large B-Cell Lymphoma;   Mycosis Fungoides;   Nasal Type Extranodal NK/T-Cell Lymphoma;   Nodal Marginal Zone Lymphoma;   Peripheral T-Cell Lymphoma, Not Otherwise Specified;   Post-Transplant Lymphoproliferative Disorder;   Primary Cutaneous Anaplastic Large Cell Lymphoma;   Primary Effusion Lymphoma;   Sezary Syndrome;   Splenic Marginal Zone Lymphoma;   Subcutaneous Panniculitis-Like T-Cell Lymphoma;   Systemic Anaplastic Large Cell Lymphoma;   T Lymphoblastic Leukemia/Lymphoma;   Transformed Recurrent Non-Hodgkin Lymphoma
Interventions: Other: Laboratory Biomarker Analysis;   Other: Quality-of-Life Assessment;   Other: Questionnaire Administration;   Dietary Supplement: Salvia hispanica Seed
19 Recruiting Safety and Efficacy Study of BCD-020 in Therapy of Non-Hodgkin's Lymphoma
Conditions: Follicular Non-Hodgkin's Lymphoma;   Nodal Marginal Zone Lymphoma;   Splenic Marginal Zone Lymphoma
Intervention: Biological: rituximab
20 Recruiting A Phase 1, Open-label Trial of Oral Azacitidine (CC-486) Plus RCHOP in Subjects With Large B-Cell Lymphoma or Follicular Lymphoma or Transformed Lymphoma
Conditions: Lymphoma, Large B-Cell, Diffuse;   Lymphoma, Follicular
Interventions: Drug: Oral Azacitidine;   Drug: Rituximab;   Drug: cyclophosphamide;   Drug: Vincristine;   Drug: Prednisone

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years